Cargando…
Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer
BACKGROUND: Treatment outcomes appear to be better for ovarian cancer (OC) patients carrying the BRCA1/2 germline mutation than for patients with sporadic OC. However, most published data are for North American, British and Jewish populations. There have been very few studies on treatment outcomes i...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724399/ https://www.ncbi.nlm.nih.gov/pubmed/26807161 http://dx.doi.org/10.1186/s13053-015-0041-2 |
_version_ | 1782411553584185344 |
---|---|
author | Szatkowski, Wiktor Blecharz, Paweł Mituś, Jerzy W. Jasiówka, Marek Łuczyńska, Elżbieta Jakubowicz, Jerzy Byrski, Tomasz |
author_facet | Szatkowski, Wiktor Blecharz, Paweł Mituś, Jerzy W. Jasiówka, Marek Łuczyńska, Elżbieta Jakubowicz, Jerzy Byrski, Tomasz |
author_sort | Szatkowski, Wiktor |
collection | PubMed |
description | BACKGROUND: Treatment outcomes appear to be better for ovarian cancer (OC) patients carrying the BRCA1/2 germline mutation than for patients with sporadic OC. However, most published data are for North American, British and Jewish populations. There have been very few studies on treatment outcomes in Central and Eastern European patients with OC. The aim of this study was to analyse prognostic factors in Polish patients with BRCA1-dependent OC (BRCA1-OC). METHODS: The records of patients with OC treated with surgery and chemotherapy at the Centre of Oncology in Kraków, Poland, between 2004 and 2009 were reviewed. Based on family history, a group of 249 consecutive patients fulfilling the criteria for risk of hereditary OC were selected and tested for the germline BRCA1 mutation. Response to combination therapy (surgery and chemotherapy) in the BRCA1-OC group was assessed based on clinical examination, imaging and serum CA125. RESULTS: Germline BRCA1 mutations were detected in 69 of the 249 patients, but three of these patients failed to complete the study. Finally, 66 patients with BRCA1-OC were included in the study group. The median age of the study patients was 49.5 years. All had undergone primary or interval cytoreductive surgery and chemotherapy. Progression occurred in 48 (72.7 %) of the 66 patients and median time to progression was 20 months. The 5-year overall survival rate in was 43.9 % and median survival time was 32.3 months. On multivariate analysis, the endometrial subtype of OC and serum CA125 < 12.5 U/ml at the end of treatment were independent, positive prognostic factors for 5-year overall survival. CONCLUSION: Prognostic factors for favourable treatment outcomes in Polish patients with BRCA1-OC do not appear to differ from those in patients with sporadic OC. The incidence of the endometrial subtype of OC was relatively high (34.9 %) among women in the study. This was unexpected and has not been reported previously. This subtype of OC was an independent prognostic factor for favourable treatment outcomes. |
format | Online Article Text |
id | pubmed-4724399 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47243992016-01-25 Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer Szatkowski, Wiktor Blecharz, Paweł Mituś, Jerzy W. Jasiówka, Marek Łuczyńska, Elżbieta Jakubowicz, Jerzy Byrski, Tomasz Hered Cancer Clin Pract Research BACKGROUND: Treatment outcomes appear to be better for ovarian cancer (OC) patients carrying the BRCA1/2 germline mutation than for patients with sporadic OC. However, most published data are for North American, British and Jewish populations. There have been very few studies on treatment outcomes in Central and Eastern European patients with OC. The aim of this study was to analyse prognostic factors in Polish patients with BRCA1-dependent OC (BRCA1-OC). METHODS: The records of patients with OC treated with surgery and chemotherapy at the Centre of Oncology in Kraków, Poland, between 2004 and 2009 were reviewed. Based on family history, a group of 249 consecutive patients fulfilling the criteria for risk of hereditary OC were selected and tested for the germline BRCA1 mutation. Response to combination therapy (surgery and chemotherapy) in the BRCA1-OC group was assessed based on clinical examination, imaging and serum CA125. RESULTS: Germline BRCA1 mutations were detected in 69 of the 249 patients, but three of these patients failed to complete the study. Finally, 66 patients with BRCA1-OC were included in the study group. The median age of the study patients was 49.5 years. All had undergone primary or interval cytoreductive surgery and chemotherapy. Progression occurred in 48 (72.7 %) of the 66 patients and median time to progression was 20 months. The 5-year overall survival rate in was 43.9 % and median survival time was 32.3 months. On multivariate analysis, the endometrial subtype of OC and serum CA125 < 12.5 U/ml at the end of treatment were independent, positive prognostic factors for 5-year overall survival. CONCLUSION: Prognostic factors for favourable treatment outcomes in Polish patients with BRCA1-OC do not appear to differ from those in patients with sporadic OC. The incidence of the endometrial subtype of OC was relatively high (34.9 %) among women in the study. This was unexpected and has not been reported previously. This subtype of OC was an independent prognostic factor for favourable treatment outcomes. BioMed Central 2016-01-23 /pmc/articles/PMC4724399/ /pubmed/26807161 http://dx.doi.org/10.1186/s13053-015-0041-2 Text en © Szatkowski et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Szatkowski, Wiktor Blecharz, Paweł Mituś, Jerzy W. Jasiówka, Marek Łuczyńska, Elżbieta Jakubowicz, Jerzy Byrski, Tomasz Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer |
title | Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer |
title_full | Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer |
title_fullStr | Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer |
title_full_unstemmed | Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer |
title_short | Prognostic factors in Polish patients with BRCA1-dependent ovarian cancer |
title_sort | prognostic factors in polish patients with brca1-dependent ovarian cancer |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4724399/ https://www.ncbi.nlm.nih.gov/pubmed/26807161 http://dx.doi.org/10.1186/s13053-015-0041-2 |
work_keys_str_mv | AT szatkowskiwiktor prognosticfactorsinpolishpatientswithbrca1dependentovariancancer AT blecharzpaweł prognosticfactorsinpolishpatientswithbrca1dependentovariancancer AT mitusjerzyw prognosticfactorsinpolishpatientswithbrca1dependentovariancancer AT jasiowkamarek prognosticfactorsinpolishpatientswithbrca1dependentovariancancer AT łuczynskaelzbieta prognosticfactorsinpolishpatientswithbrca1dependentovariancancer AT jakubowiczjerzy prognosticfactorsinpolishpatientswithbrca1dependentovariancancer AT byrskitomasz prognosticfactorsinpolishpatientswithbrca1dependentovariancancer |